Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
Biologic therapies for autoinflammatory and autoimmune diseases
Kiniksa Pharmaceuticals International is a commercial-stage biopharmaceutical company focused on acquiring, developing and commercialising medicines for autoinflammatory and autoimmune diseases with significant unmet need. Its approved product, rilonacept, is an IL-1 inhibitor indicated for recurrent pericarditis. The…
Generic and branded prescription medicines development and supply
Northumbria Pharma is a pharmaceutical company specialising in the development, manufacture, licensing, and supply of generic and branded prescription medicines across primary and secondary care. Its portfolio spans multiple therapeutic areas including rare diseases, neurology, respiratory, and oncology supportive…
Cell-based platform for next-generation mRNA medicines
Sensible Biotechnologies is a biotechnology company developing a cell-based platform for the design, optimisation, and manufacturing of high-quality mRNA. Using engineered living cells and precision fermentation, the platform produces low-immunogenicity mRNA at scale, addressing fundamental limitations of conventional…
Oncolytic viral therapies engineered for intravenous cancer treatment
Theolytics is a clinical-stage biotechnology company developing oncolytic viral therapies for cancer. Its phenotypic screening platform enables the discovery and development of adenovirus-based candidates optimised for intravenous delivery and specific patient populations. The lead programme, THEO-260, entered Phase…
Oncolytic vaccinia virus platform targeting refractory solid tumours
VacV Biotherapeutics is a cancer immunotherapy company developing engineered oncolytic Vaccinia virus-based therapeutics for the treatment of solid tumours. Spun out of Barts Cancer Institute and Queen Mary University of London, the company's platform uses a modified Vaccinia virus to simultaneously destroy tumour…
Cambridge R&D hub for GPCR-based drug discovery
Nxera Pharma UK is the Cambridge-based drug discovery arm of Tokyo-listed Nxera Pharma, formerly Sosei Heptares, operating from Granta Park with approximately 170 scientists. Its structure-based drug discovery capabilities have produced over 50 resolved GPCR structures. Following a restructuring in November 2025, the…
Fragment-based drug discovery platform for oncology and CNS disorders
Astex Pharmaceuticals is a drug discovery and development company pioneering fragment-based drug discovery through its proprietary Pyramid platform, applied to oncology and central nervous system disorders. Astex maintains an internal pipeline alongside active collaborations with MSD targeting KRAS and p53. The…
AI-guided RNA therapies for chronic metabolic diseases
Elarna Bio is a biotechnology company developing long-acting RNA therapeutics for chronic metabolic diseases. It combines AI-driven discovery with RNA engineering to improve the duration of therapeutic activity. The platform focuses on challenges associated with liver-targeted RNA treatments and is intended for…
Bispecific antibody-drug conjugates for cancer-selective precision therapy
BiVictriX Therapeutics is a biopharmaceutical company developing bispecific antibody-drug conjugates for targeted cancer treatment. Its Bi-Cygni platform recognises combinations of two tumour-associated antigens to improve cancer-cell selectivity and limit effects on healthy tissues. Its lead solid-tumour candidate,…
AAV gene therapy company targeting inherited and common retinal diseases
Beacon Therapeutics is a clinical-stage UK biopharma company developing adeno-associated virus (AAV) gene therapies for retinal diseases causing blindness. Its lead programme, laru-zova (AGTC-501), is in Phase II/III clinical trials for X-linked retinitis pigmentosa. The pipeline also includes preclinical programmes…
Stem cell therapies for equine musculoskeletal injuries
BioDivide Limited is a regenerative medicine company developing and commercialising stem cell therapies, with a current focus on equine musculoskeletal conditions. Its product uses a non-invasive proprietary method to collect and process stem cells from horses, delivering a standardised, frozen, ready-to-inject…
ML platform designing optimised CAR-T and BiTE therapies
Coding Bio is a biotechnology company using machine learning and high-throughput screening to design chimeric antigen receptor and bispecific T cell engager therapies. The company's platform screens millions of modular protein candidates in living cells to identify designs that best induce immune responses, generating…
AI-driven tRNA synthetase platform for novel small molecule therapeutics
Oxford Drug Design is an Oxford biotech developing small molecule therapeutics using an integrated platform combining aminoacyl-tRNA synthetase biology with proprietary generative AI and machine learning. The platform provides structural biology knowledge, crystallographic data, and novel chemotypes targeting tRNA…
Pharma-university venture funding early-stage translational research
Apollo Therapeutics is a biopharma company advancing therapeutic programmes derived from research at partner universities including Cambridge, Imperial College London, UCL, King's College London, and the Institute of Cancer Research. Originally a joint venture between three universities and AstraZeneca, GSK, and…
Broad-spectrum intranasal antivirals targeting respiratory viral infections
Pneumagen is a Scottish clinical-stage biotechnology company developing broad-spectrum intranasal antiviral therapies. Pneumagen's platform generates multivalent carbohydrate binding molecules (mCBMs) that block viral entry by binding to sialic acid residues on host epithelial cells. In 2026, Pneumagen reorganized…
Multispecific immune cell engagers targeting gamma delta T cells
Cytospire Therapeutics is developing multispecific engager antibodies designed to enhance and direct the activity of gamma delta T cells for the treatment of cancer and autoimmune disease. The company emerged from stealth in 2024, backed by Abingworth, 4BIO Capital and LifeArc Ventures. Its platform targets both…
Novel mRNA technology platform for safer, faster vaccines
CamMed Therapeutics (Cambridge Medixine Ltd) is a preclinical biotechnology company developing a novel mRNA technology platform for vaccines and therapeutics. Inspired by natural biological phenomena, its engineered RNA molecules are designed to deliver safer, easier and faster medicines to the clinic while reducing…
Long-acting GnRH antagonist for prostate cancer and urinary retention
Antev is a clinical-stage biopharmaceutical company developing a long-acting gonadotropin-releasing hormone (GnRH) antagonist that suppresses testosterone production. Its lead peptide therapy is being developed for men with advanced prostate cancer, including those at high cardiovascular risk, and for men experiencing…
VNAR antibody shuttles for brain-targeted biologic therapies
Ossianix is a biopharmaceutical company developing single-domain VNAR antibody platforms for targeted delivery of therapeutics across the blood-brain barrier. Its TXP1 shuttle binds transferrin receptor 1 to transport antibody-based medicines into the central nervous system. The company engineers antibody fusions and…
Specialty biopharma with UK neurotoxin manufacturing hub
Ipsen is a French specialty biopharmaceutical company with one of three global hubs based in the UK. Its Wrexham site serves as the company's global neuroscience centre of excellence, responsible for research, development and manufacture of neurotoxin products including botulinum toxin. The London site houses…